Cargando…

Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma

Glioblastomas (GBMs) are the most aggressive and lethal primary astrocytic tumors in adults, with very poor prognosis. Recurrence in GBM is attributed to glioblastoma stem-like cells (GSLCs). The behavior of the tumor, including proliferation, progression, invasion, and significant resistance to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Néant, Isabelle, Haiech, Jacques, Kilhoffer, Marie-Claude, Aulestia, Francisco J., Moreau, Marc, Leclerc, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305344/
https://www.ncbi.nlm.nih.gov/pubmed/30618619
http://dx.doi.org/10.3389/fnmol.2018.00472
_version_ 1783382542280294400
author Néant, Isabelle
Haiech, Jacques
Kilhoffer, Marie-Claude
Aulestia, Francisco J.
Moreau, Marc
Leclerc, Catherine
author_facet Néant, Isabelle
Haiech, Jacques
Kilhoffer, Marie-Claude
Aulestia, Francisco J.
Moreau, Marc
Leclerc, Catherine
author_sort Néant, Isabelle
collection PubMed
description Glioblastomas (GBMs) are the most aggressive and lethal primary astrocytic tumors in adults, with very poor prognosis. Recurrence in GBM is attributed to glioblastoma stem-like cells (GSLCs). The behavior of the tumor, including proliferation, progression, invasion, and significant resistance to therapies, is a consequence of the self-renewing properties of the GSLCs, and their high resistance to chemotherapies have been attributed to their capacity to enter quiescence. Thus, targeting GSLCs may constitute one of the possible therapeutic challenges to significantly improve anti-cancer treatment regimens for GBM. Ca(2+) signaling is an important regulator of tumorigenesis in GBM, and the transition from proliferation to quiescence involves the modification of the kinetics of Ca(2+) influx through store-operated channels due to an increased capacity of the mitochondria of quiescent GSLC to capture Ca(2+). Therefore, the identification of new therapeutic targets requires the analysis of the calcium-regulated elements at transcriptional levels. In this review, we focus onto the direct regulation of gene expression by KCNIP proteins (KCNIP1–4). These proteins constitute the class E of Ca(2+) sensor family with four EF-hand Ca(2+)-binding motifs and control gene transcription directly by binding, via a Ca(2+)-dependent mechanism, to specific DNA sites on target genes, called downstream regulatory element (DRE). The presence of putative DRE sites on genes associated with unfavorable outcome for GBM patients suggests that KCNIP proteins may contribute to the alteration of the expression of these prognosis genes. Indeed, in GBM, KCNIP2 expression appears to be significantly linked to the overall survival of patients. In this review, we summarize the current knowledge regarding the quiescent GSLCs with respect to Ca(2+) signaling and discuss how Ca(2+) via KCNIP proteins may affect prognosis genes expression in GBM. This original mechanism may constitute the basis of the development of new therapeutic strategies.
format Online
Article
Text
id pubmed-6305344
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63053442019-01-07 Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma Néant, Isabelle Haiech, Jacques Kilhoffer, Marie-Claude Aulestia, Francisco J. Moreau, Marc Leclerc, Catherine Front Mol Neurosci Neuroscience Glioblastomas (GBMs) are the most aggressive and lethal primary astrocytic tumors in adults, with very poor prognosis. Recurrence in GBM is attributed to glioblastoma stem-like cells (GSLCs). The behavior of the tumor, including proliferation, progression, invasion, and significant resistance to therapies, is a consequence of the self-renewing properties of the GSLCs, and their high resistance to chemotherapies have been attributed to their capacity to enter quiescence. Thus, targeting GSLCs may constitute one of the possible therapeutic challenges to significantly improve anti-cancer treatment regimens for GBM. Ca(2+) signaling is an important regulator of tumorigenesis in GBM, and the transition from proliferation to quiescence involves the modification of the kinetics of Ca(2+) influx through store-operated channels due to an increased capacity of the mitochondria of quiescent GSLC to capture Ca(2+). Therefore, the identification of new therapeutic targets requires the analysis of the calcium-regulated elements at transcriptional levels. In this review, we focus onto the direct regulation of gene expression by KCNIP proteins (KCNIP1–4). These proteins constitute the class E of Ca(2+) sensor family with four EF-hand Ca(2+)-binding motifs and control gene transcription directly by binding, via a Ca(2+)-dependent mechanism, to specific DNA sites on target genes, called downstream regulatory element (DRE). The presence of putative DRE sites on genes associated with unfavorable outcome for GBM patients suggests that KCNIP proteins may contribute to the alteration of the expression of these prognosis genes. Indeed, in GBM, KCNIP2 expression appears to be significantly linked to the overall survival of patients. In this review, we summarize the current knowledge regarding the quiescent GSLCs with respect to Ca(2+) signaling and discuss how Ca(2+) via KCNIP proteins may affect prognosis genes expression in GBM. This original mechanism may constitute the basis of the development of new therapeutic strategies. Frontiers Media S.A. 2018-12-18 /pmc/articles/PMC6305344/ /pubmed/30618619 http://dx.doi.org/10.3389/fnmol.2018.00472 Text en Copyright © 2018 Néant, Haiech, Kilhoffer, Aulestia, Moreau and Leclerc. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Néant, Isabelle
Haiech, Jacques
Kilhoffer, Marie-Claude
Aulestia, Francisco J.
Moreau, Marc
Leclerc, Catherine
Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title_full Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title_fullStr Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title_full_unstemmed Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title_short Ca(2+)-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma
title_sort ca(2+)-dependent transcriptional repressors kcnip and regulation of prognosis genes in glioblastoma
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305344/
https://www.ncbi.nlm.nih.gov/pubmed/30618619
http://dx.doi.org/10.3389/fnmol.2018.00472
work_keys_str_mv AT neantisabelle ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma
AT haiechjacques ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma
AT kilhoffermarieclaude ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma
AT aulestiafranciscoj ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma
AT moreaumarc ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma
AT leclerccatherine ca2dependenttranscriptionalrepressorskcnipandregulationofprognosisgenesinglioblastoma